Last updated: May 28, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07045415 | — | The Effect of Pelvic Floor Muscle Exercises After Radical Prostatectomy | Unknown mechanism |
| NCT05939414 | 3 | An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | PSMA -- radioligand therapy (177Lu-PSMA) |
| NCT06353386 | 1, 2 | Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Unknown mechanism |
| NCT06508567 | — | Salvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era | Unknown mechanism |
| NCT06492122 | 1 | Study With [225Ac]Ac-FL-020 in mCRPC Participants | PSMA -- targeted alpha therapy (radioligand therapy) |
| Sponsor | Recruiting trials |
|---|---|
| University Health Network, Toronto | 22 |
| Mayo Clinic | 15 |
| M.D. Anderson Cancer Center | 15 |
| National Cancer Institute (NCI) | 14 |
| Memorial Sloan Kettering Cancer Center | 14 |
Countries/regions with the most active trial sites for prostate cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Mar 2028 | NCT05896371 | A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy | Prostate-specific membrane antigen (PSMA) -- radioligand therapy with lutetium-177 labeled PSMA ligand |
| Jul 2026 | NCT07581184 | A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer | PSMA -- targeted alpha-particle radioligand therapy |
| Jun 15, 2026 | NCT07567521 | A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC | Prostate-specific membrane antigen (PSMA) -- radiopharmaceutical therapy (TRC003) |
| Jun 1, 2026 | NCT07495293 | Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer | Carbon ions -- ultra-hypofractionated carbon ion radiotherapy |
| Jun 2026 | NCT07316686 | Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma | Prostate-Specific Membrane Antigen (PSMA) -- targeted radioligand therapy with 177Lu-PSMA-I&T combined with docetaxel chemotherapy |
| Jun 2026 | NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | JAK1/2 + Androgen receptor -- kinase inhibition + pathway inhibition (JAK inhibitor + AR pathway inhibitor) |
| May 25, 2026 | NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | PSMA + 4-1BB -- bispecific antibody; PD-1 -- immune checkpoint inhibitor; PSMA + CD3 -- bispecific antibody |
| May 18, 2026 | NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer | STEAP2 -- bispecific T-cell engager (TCE) |
You've seen the prostate cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.